The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Olaparib monotherapy in pretreated patients with BRCA1/2 alterations: Results of a DRUP trial cohort.
 
Hanneke van der Wijngaart
No Relationships to Disclose
 
Louisa Rose Hoes
No Relationships to Disclose
 
Jade Maxime van Berge Henegouwen
No Relationships to Disclose
 
Daphne Liselotte van Der Velden
No Relationships to Disclose
 
Laurien Zeverijn
No Relationships to Disclose
 
Paul Roepman
No Relationships to Disclose
 
Luan Nguyen
No Relationships to Disclose
 
Erik D. van Werkhoven
No Relationships to Disclose
 
Wendy W.J. de Leng
No Relationships to Disclose
 
Anne M.L. Jansen
No Relationships to Disclose
 
Niven Mehra
No Relationships to Disclose
 
Debbie Robbrecht
Consulting or Advisory Role - Bayer; Cantargia AB; Faron Pharmaceuticals; Servier (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Hans Gelderblom
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst)
 
Emile E. Voest
Consulting or Advisory Role - Biogeneration Ventures; InteRNA; Netherlands Cancer Institute (Inst); Servier (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Henk M.W. Verheul
Consulting or Advisory Role - Glycostem (Inst); lava therapeutics (Inst)
Research Funding - Pfizer; Roche